A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes

NCT01455870 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

535

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: ITCA 650 60 mcg/day
DRUG: sitagliptin

Sponsor

Intarcia Therapeutics